Noteboom, Samantha http://orcid.org/0000-0003-4796-8636
Seiler, Moritz
Chien, Claudia http://orcid.org/0000-0001-8280-9513
Rane, Roshan P. http://orcid.org/0000-0002-3996-2034
Barkhof, Frederik http://orcid.org/0000-0003-3543-3706
Strijbis, Eva M. M. http://orcid.org/0000-0001-6705-5864
Paul, Friedemann http://orcid.org/0000-0002-6378-0070
Schoonheim, Menno M. http://orcid.org/0000-0002-2504-6959
Ritter, Kerstin http://orcid.org/0000-0001-7115-0020
Funding for this research was provided by:
DeSBI Research Unit (DFG, KI-FOR 5363, Project ID 459422098)
Deutschen Multiple Sklerose Gesellschaft
Fondation Eugène Devic EDMUS contre la Sclérose en Plaques & Observatoire Français de la Sclérose en Plaques (Deep MS)
ZonMW (09150172010056)
Stichting MS Research (08-650, 13-820, 14-358e)
Article History
Received: 29 February 2024
Revised: 1 June 2024
Accepted: 9 June 2024
First Online: 23 June 2024
Declarations
:
: SN was supported by research grants from Atara Biotherapeutics, Merck and Biogen. CC reported grants from Novartis and Alexion during the conduct of the study, is part of a consortium project funded by the U.S. Department of Defense, and has a non-financial affiliation as a member from the Canadian Institutes of Health Research Standing Committee on Science outside the submitted work. FB is a steering committee or Data Safety Monitoring Board member for Biogen, Merck, ATRI/ACTC and Prothena; a consultant for Roche, Celltrion, Rewind Therapeutics, Merck, IXICO, Jansen and Combinostics; and has research agreements with Merck, Biogen, GE Healthcare and Roche. EMMS serves on the editorial board of Frontiers in Neurology received speaker fees from Merck and Novartis. FP served on the scientific advisory boards of Novartis and MedImmune; received travel funding and/or speaker honoraria from Bayer, Novartis, Biogen, Teva, Sanofi-Aventis/Genzyme, Merck Serono, Alexion, Chugai, MedImmune, and Shire; is an associate editor of Neurology: Neuroimmunology & Neuroinflammation; is an academic editor of PLoS ONE; consulted for Sanofi Genzyme, Biogen, MedImmune, Shire, and Alexion; received research support from Bayer, Novartis, Biogen, Teva, Sanofi-Aventis/Geynzme, Alexion, and Merck Serono; and received research support from the German Research Council, Werth Stiftung of the City of Cologne, German Ministry of Education and Research, Arthur Arnstein Stiftung Berlin, EU FP7 Framework Program, Arthur Arnstein Foundation Berlin, Guthy-Jackson Charitable Foundation, and NMSS. MMS serves on the editorial board of Neurology and Frontiers in Neurology, receives research support from the Dutch MS Research Foundation, Eurostars-EUREKA, ARSEP, Amsterdam Neuroscience, MAGNIMS and ZonMW (Vidi grant, project number 09150172010056) and has served as a consultant for or received research support from Atara Biotherapeutics. No other disclosures were reported.